Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan I Silverberg

Showing results (321-330 of 667) with videos related to

Pageof 67
Sort By:
Archives of Dermatological Research|September 17, 2021
Atopic dermatitis is not associated with SARS-CoV-2 outcomesUros Rakita, Trisha Kaundinya, Armaan Guraya, et al.
Dermatology and Therapy|November 5, 2022
Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS)Jonathan I Silverberg, Eric L Simpson, Brian M Calimlim, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)Jonathan I Silverberg, Robert Bissonnette, Leon Kircik, et al.
Archives of Dermatological Research|November 13, 2021
Associations between onychomycosis and COVID-19 clinical outcomes: a retrospective cohort study from a US metropolitan centerUros Rakita, Trisha Kaundinya, Armaan Guraya, et al.
American Journal of Clinical Dermatology|August 30, 2018
A Comprehensive Conceptual Model of the Experience of Chronic Itch in AdultsJonathan I Silverberg, Robert W Kantor, Prarthana Dalal, et al.
Dermatology and Therapy|February 4, 2025
Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DAREJonathan I Silverberg, Eric L Simpson, Andrew E Pink, et al.
Archives of Dermatological Research|March 12, 2025
Burden of mild and moderate atopic dermatitis in adults: results from a real-world study in the United StatesJonathan I Silverberg, Peter Anderson, Joseph C Cappelleri, et al.
Dermatology and Therapy|July 30, 2024
Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic DermatitisApril W Armstrong, H Chih-Ho Hong, Brian M Calimlim, et al.
Archives of Dermatological Research|March 20, 2024
Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severityJonathan I Silverberg, Tove Agner, Keith Baranowski, et al.
The Journal of Investigative Dermatology|May 19, 2016
Atopic Dermatitis Is Associated with Less Physical Activity in US AdultsJonathan I Silverberg, Jing Song, Daniel Pinto, et al.
Pageof 67

Showing results (321-330 of 667) with videos related to

Sort By:
Pageof 67
Archives of Dermatological Research|September 17, 2021
Atopic dermatitis is not associated with SARS-CoV-2 outcomesUros Rakita, Trisha Kaundinya, Armaan Guraya, et al.
Dermatology and Therapy|November 5, 2022
Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS)Jonathan I Silverberg, Eric L Simpson, Brian M Calimlim, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)Jonathan I Silverberg, Robert Bissonnette, Leon Kircik, et al.
Archives of Dermatological Research|November 13, 2021
Associations between onychomycosis and COVID-19 clinical outcomes: a retrospective cohort study from a US metropolitan centerUros Rakita, Trisha Kaundinya, Armaan Guraya, et al.
American Journal of Clinical Dermatology|August 30, 2018
A Comprehensive Conceptual Model of the Experience of Chronic Itch in AdultsJonathan I Silverberg, Robert W Kantor, Prarthana Dalal, et al.
Dermatology and Therapy|February 4, 2025
Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DAREJonathan I Silverberg, Eric L Simpson, Andrew E Pink, et al.
Archives of Dermatological Research|March 12, 2025
Burden of mild and moderate atopic dermatitis in adults: results from a real-world study in the United StatesJonathan I Silverberg, Peter Anderson, Joseph C Cappelleri, et al.
Dermatology and Therapy|July 30, 2024
Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic DermatitisApril W Armstrong, H Chih-Ho Hong, Brian M Calimlim, et al.
Archives of Dermatological Research|March 20, 2024
Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severityJonathan I Silverberg, Tove Agner, Keith Baranowski, et al.
The Journal of Investigative Dermatology|May 19, 2016
Atopic Dermatitis Is Associated with Less Physical Activity in US AdultsJonathan I Silverberg, Jing Song, Daniel Pinto, et al.
Pageof 67